Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Scientists in China have developed a modified virus that causes cancer cells to make sugars normally found in pigs, causing ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

For Kelly Heather, 38, from Gravesend, it was a positive moment, after what had been a difficult few years. But then, on December 2, she had a seizure and was later diagnosed with a brain tumour.

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

A YEAR on from the second of two devastating cancer diagnoses, Sarah Ferguson is looking forward to a brighter 2025. The Duchess of York, 65, was diagnosed with an aggressive form of skin cancer a ...

Replimune Group Inc . (NASDAQ:REPL), currently trading at $11.70, saw its price target increased to $27.00 from $18.00 by BMO Capital, with the firm maintaining an Outperform rating on the stock.

Whatever form it takes, successful treatment reverses the changes in brain circuitry that make substance use hard to control. Yet many factors other than biology must be addressed for treatment to ...